Raphi Levy Sells 2,270 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,270 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $14.00, for a total value of $31,780.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,262,520. This trade represents a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total value of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

DRTS stock opened at $12.78 on Thursday. The firm has a 50 day moving average of $10.15 and a two-hundred day moving average of $8.08. Alpha Tau Medical Ltd. has a 12 month low of $2.87 and a 12 month high of $14.11. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -19.07 and a beta of 1.17. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). As a group, equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DRTS has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Piper Sandler boosted their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. LADENBURG THALM/SH SH upped their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Citigroup increased their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Finally, Barclays boosted their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Alpha Tau Medical presently has a consensus rating of “Hold” and a consensus target price of $12.60.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DRTS. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical in the third quarter valued at approximately $62,000. Bank of America Corp DE increased its position in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares during the period. Millennium Management LLC acquired a new position in Alpha Tau Medical during the 3rd quarter valued at $170,000. Mariner LLC raised its stake in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after purchasing an additional 80,129 shares during the last quarter. Finally, Apella Capital LLC bought a new stake in Alpha Tau Medical in the 4th quarter valued at $1,892,000. 2.65% of the stock is owned by institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.